Innovation: To overcome a peanut allergy, wear a little peanut patch

Next Steps

Efren Rael, clinical director at Stanford’s allergy research center, says he thinks Viaskin will be effective as long as people can be trusted to use it daily. He says it may be slower than a therapy in which patients directly ingest trace amounts of peanuts; DBV declined to compare the two treatments. It’ll seek U.S. and European Union regulatory approval for the patch following a yearlong Phase III trial with 330 patients, which began in December.